Oncology Imaging

Researchers from Mount Sinai in New York have pinpointed a new biomarker that may ultimately provide individualized treatment in patients with an aggressive form of bladder cancer.

University of Kansas (KU) Cancer Center researchers have launched a clinical trial eliminating radiation therapy from treatment for the invasive type of breast cancer that affects nearly a fifth of all breast cancer patients, according to a KU news release.

A large study utilizing automated mammography revealed a higher cancer rate in women with dense breast tissue compared to those with less-dense breasts, according to recent research published in Radiology

Studies examining breast cancer risk and treatment outcomes are not adequately incorporating race and socioeconomic factors such as education level and economic status, according to a Johns Hopkins release.

A study of more than 15,000 childhood cancer survivors found a “surprisingly” high number lacked concern for their well-being in adulthood—despite the group’s increased health risks. Some 40 percent were unconcerned about developing new cancers.

Valerie Powell, a program coordinator with the University of Alabama at Birmingham’s department of radiation oncology struggled for eight years trying to figure out why a lump had formed under her jawline, with little help from CT and MRI.

A new molecular imaging system developed by researchers from the University of Illinois can show living tissue in great detail and may allow researchers to monitor cancerous cells as they progress inside the body.

“This study provides strong support that vitamin D plays an important role in breast cancer prevention,” said co-author of the study Joan M. Lappe, PhD, in a statement. “It also demonstrates that blood levels of vitamin D for breast cancer prevention need to be higher than currently recommended levels for bone health.”

"Our findings show that people have a strong desire to do something to address the threat of cancer and that they would prefer to receive a screening test that does not save lives rather than not be screened at all," said lead author Laura Scherer, PhD.

Researchers from the University of Michigan Rogel Cancer Center have discovered a new subtype of prostate cancer that occurs in about 7 percent of patients.

Several aspects of cancer-related cognitive impairment are currently unknown, including why it occurs, how long it lasts and what other health problems it causes. But the real mystery lies in the wide-ranging estimates of how many cancer patients “chemobrain” actually impacts, according to an article in the Los Angeles Times.

A multicenter clinical trial underway at UT Southwestern in Dallas is testing a new technique that would avoid nerve bundles and arteries commonly affected during prostate cancer radiation therapy in hopes of preserving patients’ sexual function.